236 related articles for article (PubMed ID: 26879872)
1. CCR9 in cancer: oncogenic role and therapeutic targeting.
Tu Z; Xiao R; Xiong J; Tembo KM; Deng X; Xiong M; Liu P; Wang M; Zhang Q
J Hematol Oncol; 2016 Feb; 9():10. PubMed ID: 26879872
[TBL] [Abstract][Full Text] [Related]
2. CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide.
Sharma PK; Singh R; Novakovic KR; Eaton JW; Grizzle WE; Singh S
Int J Cancer; 2010 Nov; 127(9):2020-30. PubMed ID: 20127861
[TBL] [Abstract][Full Text] [Related]
3. CCR9 and CCL25: A review of their roles in tumor promotion.
Xu B; Deng C; Wu X; Ji T; Zhao L; Han Y; Yang W; Qi Y; Wang Z; Yang Z; Yang Y
J Cell Physiol; 2020 Dec; 235(12):9121-9132. PubMed ID: 32401349
[TBL] [Abstract][Full Text] [Related]
4. CCR9-mediated signaling through β-catenin and identification of a novel CCR9 antagonist.
Lee S; Heinrich EL; Li L; Lu J; Choi AH; Levy RA; Wagner JE; Yip ML; Vaidehi N; Kim J
Mol Oncol; 2015 Oct; 9(8):1599-611. PubMed ID: 26003048
[TBL] [Abstract][Full Text] [Related]
5. CCL25/CCR9 Signal Promotes Migration and Invasion in Hepatocellular and Breast Cancer Cell Lines.
Zhang Z; Sun T; Chen Y; Gong S; Sun X; Zou F; Peng R
DNA Cell Biol; 2016 Jul; 35(7):348-57. PubMed ID: 27008282
[TBL] [Abstract][Full Text] [Related]
6. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion.
Johnson-Holiday C; Singh R; Johnson EL; Grizzle WE; Lillard JW; Singh S
World J Surg Oncol; 2011 May; 9():46. PubMed ID: 21539750
[TBL] [Abstract][Full Text] [Related]
7. Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer.
Singh R; Stockard CR; Grizzle WE; Lillard JW; Singh S
Int J Oncol; 2011 Aug; 39(2):373-81. PubMed ID: 21637913
[TBL] [Abstract][Full Text] [Related]
8. CCL25 chemokine-guided stem cell attraction: an assessment of possible benefits and risks.
Spinnen J; Ringe J; Sittinger M
Regen Med; 2018 Oct; 13(7):833-844. PubMed ID: 30284497
[TBL] [Abstract][Full Text] [Related]
9. CCR9 Antagonists in the Treatment of Ulcerative Colitis.
Bekker P; Ebsworth K; Walters MJ; Berahovich RD; Ertl LS; Charvat TT; Punna S; Powers JP; Campbell JJ; Sullivan TJ; Jaen JC; Schall TJ
Mediators Inflamm; 2015; 2015():628340. PubMed ID: 26457007
[TBL] [Abstract][Full Text] [Related]
10. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease.
Apostolaki M; Manoloukos M; Roulis M; Wurbel MA; Müller W; Papadakis KA; Kontoyiannis DL; Malissen B; Kollias G
Gastroenterology; 2008 Jun; 134(7):2025-35. PubMed ID: 18439426
[TBL] [Abstract][Full Text] [Related]
11. CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands.
Korbecki J; Grochans S; Gutowska I; Barczak K; Baranowska-Bosiacka I
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076281
[TBL] [Abstract][Full Text] [Related]
12. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion.
Johnson EL; Singh R; Singh S; Johnson-Holiday CM; Grizzle WE; Partridge EE; Lillard JW
World J Surg Oncol; 2010 Jul; 8():62. PubMed ID: 20649989
[TBL] [Abstract][Full Text] [Related]
13. Chemokine 25-induced signaling suppresses colon cancer invasion and metastasis.
Chen HJ; Edwards R; Tucci S; Bu P; Milsom J; Lee S; Edelmann W; Gümüs ZH; Shen X; Lipkin S
J Clin Invest; 2012 Sep; 122(9):3184-96. PubMed ID: 22863617
[TBL] [Abstract][Full Text] [Related]
14. Chemokine (C-C motif) ligand 25 expressed by trophoblast cells and leukocytes bearing its receptor Ccr9: An alliance during embryo implantation?
Weingrill RB; Hoshida MS; Martinhago CD; Correa-Silva S; Cardoso E; Palmeira P; Marinho CRF; Bevilacqua E
Am J Reprod Immunol; 2018 Jan; 79(1):. PubMed ID: 29154408
[TBL] [Abstract][Full Text] [Related]
15. CCL25/CCR9 interactions regulate the function of iNKT cells in oxazolone-induced colitis in mice.
Zhu S; Bing Y; Wang X; Yu Q; Wang Y; Xu S; Song L; Wang X; Xia B; Zhu Y; Zhou R
PLoS One; 2014; 9(6):e100167. PubMed ID: 24936795
[TBL] [Abstract][Full Text] [Related]
16. The role of the CCL25-CCR9 axis in beta-cell function: potential for therapeutic intervention in type 2 diabetes.
Atanes P; Lee V; Huang GC; Persaud SJ
Metabolism; 2020 Dec; 113():154394. PubMed ID: 33058852
[TBL] [Abstract][Full Text] [Related]
17. CCR9/CCL25 expression in non-small cell lung cancer correlates with aggressive disease and mediates key steps of metastasis.
Gupta P; Sharma PK; Mir H; Singh R; Singh N; Kloecker GH; Lillard JW; Singh S
Oncotarget; 2014 Oct; 5(20):10170-9. PubMed ID: 25296976
[TBL] [Abstract][Full Text] [Related]
18. Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia.
Mirandola L; Chiriva-Internati M; Montagna D; Locatelli F; Zecca M; Ranzani M; Basile A; Locati M; Cobos E; Kast WM; Asselta R; Paraboschi EM; Comi P; Chiaramonte R
J Pathol; 2012 Apr; 226(5):713-22. PubMed ID: 21984373
[TBL] [Abstract][Full Text] [Related]
19. Intracellular expression profile and clinical significance of the CCR9-CCL25 chemokine receptor complex in nasopharyngeal carcinoma.
Ye LF; Huang J; Zhang LP; Chen Z
J Laryngol Otol; 2015 Oct; 129(10):1013-9. PubMed ID: 26279399
[TBL] [Abstract][Full Text] [Related]
20. LINC00853 restrains T cell acute lymphoblastic leukemia invasion and infiltration by regulating CCR9/CCL25.
Li J; Muhammad J; Xie T; Sun J; Lei Y; Wei Z; Pan S; Qin H; Shao L; Jiang D; Zhang Q
Mol Immunol; 2021 Dec; 140():267-275. PubMed ID: 34808497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
